The patients suffering from chronic kidney disease and having co-morbidities like diabetes or heart disease are always at the highest risk of hyperkalemia. This article discusses a study which was carried out to investigate the safety and efficacy of Patiromer in the patients who had CKD and also receiving renin-angiotensin-aldosterone inhibitors. The patients at the higher stage of chronic kidney disease (CKD) are always at higher risk of hyperkalemia. The risk increases in case of co-morbidities like diabetes, heart disease and if the patient is receiving renin-angiotensin-aldosterone inhibitor (RAAS).
Currently, there are very limited drugs to treat such patients. The presently available drugs like sodium polystyrene sulfonate and calcium polystyrene sulfonate are associated with serious gastrointestinal adverse events which limit their extended use. Patiromer is a recently approved…
